deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT04549363

Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin

Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin (GSK2857916)

Sponsor: GlaxoSmithKline

Conditions Multiple Myeloma
Interventions Belantamab mafodotin
Updated 15 times since 2020 Last updated: Nov 21, 2023 Started: Dec 21, 2020 Primary completion: Nov 21, 2022 Completion: Nov 21, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study has been terminated for reasons pertaining to feasibility

Other terminated trials from GlaxoSmithKline

See all terminations from GlaxoSmithKline

Other Multiple Myeloma trials with similar outcome

Browse all Multiple Myeloma trials

A PHASE3 clinical study on Multiple Myeloma, this trial is terminated or withdrawn. The trial is conducted by GlaxoSmithKline and has accumulated 15 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Apr 2022 · 5 months · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Dec 2023 · 11 months · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  3. Jan 2024 — Jul 2024 [monthly]

    Terminated PHASE3

  4. Dec 2023 — Jan 2024 [monthly]

    Terminated PHASE3

    Status: Recruiting → Terminated

  5. Jan 2023 — Dec 2023 [monthly]

    Recruiting PHASE3

▶ Show 10 earlier versions

  1. Sep 2022 — Jan 2023 [monthly]

    Recruiting PHASE3

  2. Apr 2022 — Sep 2022 [monthly]

    Recruiting PHASE3

  3. Nov 2021 — Apr 2022 [monthly]

    Recruiting PHASE3

  4. Sep 2021 — Nov 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  5. Apr 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE3

  6. Mar 2021 — Apr 2021 [monthly]

    Not Yet Recruiting PHASE3

  7. Jan 2021 — Mar 2021 [monthly]

    Not Yet Recruiting PHASE3

  8. Dec 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE3

  9. Nov 2020 — Dec 2020 [monthly]

    Not Yet Recruiting PHASE3

  10. Oct 2020 — Nov 2020 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations